Biopharmaceutical wholesalers in Japan play broader roles than their counterparts overseas. Beyond logistics and distribution, wholesalers perform a variety of tasks related to finance, safety, and commercialization. Such functions are typically cited as justification for various fees, rebates, and allowances…
HOME > TOP STORIES
TOP STORIES
-
BUSINESS Chugai’s H1 Sales Rise on Growth of Tecentriq, Kadcyla
July 27, 2021
-
BUSINESS Shionogi’s Oral COVID-19 Drug Enters PI in Japan
July 27, 2021
-
BUSINESS Moderna Vaccine’s Minimum Age Lowered to 12 in Japan
July 27, 2021
-
REGULATORY Spread of Regional Formularies Will Depend on “Human Relationships and Consensus-Building”: Professor
July 26, 2021
-
REGULATORY Chuikyo Reps Fret Negative Impact of Tougher Pledge Rule, but MHLW Says It’s Conducive to Stable Supplies
July 26, 2021
-
REGULATORY MHLW to Tighten “Written Pledge” Rule on Generic Listings to Thwart Supply Issues
July 26, 2021
-
REGULATORY Wariness Brewing within MHLW for Medical Fee to Incentivize Hospital Formularies
July 21, 2021
-
REGULATORY Japan to Receive 50 Million More Doses of Moderna Vaccine
July 21, 2021
-
REGULATORY Key MOF Official Wants Budget Neutrality, Cap to Optimize Drug Costs
July 20, 2021
-
REGULATORY Japan Approves COVID-19 Antibody Cocktail, 1st Drug for Mild Cases
July 20, 2021
-
BUSINESS Arcalis Sees Opportunities in mRNA Drugs, Eyes Tens of Billions of Yen in CDMO Sales
July 19, 2021
-
REGULATORY New Pharma Industry Vision to Set Out Roles of Wholesalers: MHLW Director
July 16, 2021
-
REGULATORY Japan to Lower Moderna Vaccine’s Minimum Age to 12
July 16, 2021
-
BUSINESS Guilty Ruling for Ono Employees Now Final and Binding: Onoact Case
July 15, 2021
-
BUSINESS Eisai Taps Continuous Manufacturing for Tazverik, Eyes Its Use for Other Oncology Assets Too
July 14, 2021
-
REGULATORY Chugai’s Antibody Cocktail Up for PAFSC Review on July 19, 4th COVID-19 Drug If Approved
July 13, 2021
-
COMMENTARY Attention Grows for INES Drug Pricing Proposal; Will It Become Next Card on Reform?
July 12, 2021
-
ACADEMIA Japan Needs Discussions on Target Population of Aducanumab: Clinician
July 12, 2021
-
BUSINESS Fueled by Roivant Deal, Sumitomo Dainippon Accelerating DX as It Looks Beyond Latuda LOE
July 9, 2021
-
BUSINESS FDA Updates Aduhelm Label to Only Cover MCI, Mild Alzheimer’s
July 9, 2021
ページ
With its first “off-year” drug price revision implemented this April, Japan has now wrapped up all the reform plans agreed upon by four state ministers in 2016 for pharmaceutical pricing. As the government has provided no further mid-term vision for…
The average ratio of female employees at managerial posts stood at just 12.5% at pharmaceutical companies operating in Japan, a Jiho survey revealed. While foreign drug makers had an average 25.0%, the ratio came to as low as 9.8% for…
Biogen’s controversial Alzheimer’s drug aducanumab was filed for Japanese regulatory approval in December. If approved, it will be the first…
Japan’s key reimbursement policy panel on December 20 approved an outline of its FY2020 drug pricing reform next April, with…
Japan will go ahead with the introduction of a cost-effectiveness assessment (CEA) scheme for drugs and medical devices in April…